NCT07234110

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

Single-center, Single-arm Exploratory Clinical Study on the Safety and Efficacy of Human CD5 Chimeric Antigen Receptor T Cell Injection CD5CART in the Treatment of Relapsed and Refractory CD5+ Hematologic Cancer Subjects

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator-initiated dose-finding clinical study with the primary objective of evaluating the safety of CD5CART in the treatment of subjects with relapsed and refractory CD5 hematological malignancies and to explore the MTD of CD5CART treatment of relapsed and refractory subjects with CD5 hematological malignancies. At the same time, the effectiveness and pharmacokinetic characteristics of CD5CART treatment of relapsed and refractory CD5 hematological tumors in subjects were explored

Conditions

• Relapsed and Refractory CD5 Hematological Tumors

Interventions

Type	Name	Description
DRUG	Fully human CD5 chimeric antigen receptor T cell injection	CA5 CART cells were reinfused

Timeline

• Start date: 2025-09-03
• Primary completion: 2027-05-31
• Completion: 2027-10-31
• First posted: 2025-11-18
• Last updated: 2025-11-18

Locations

1 site across 1 country: China